行情

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

实时行情|Nasdaq Last Sale

1.140
+0.040
+3.63%
交易中 13:14 01/28 EST
开盘
1.130
昨收
1.100
最高
1.170
最低
1.110
成交量
75.41万
成交额
--
52周最高
1.730
52周最低
0.5339
市值
1.71亿
市盈率(TTM)
-3.0875
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

LCTX 新闻

  • 里士满联储1月制造业指数升至2018年以来的最高水平
  • 新浪财经.1小时前
  • 美国1月消费者信心指数涨幅超预期 升至5个月来高点
  • 新浪财经.1小时前
  • 疫情掀起央行政策预期调整 欧洲出现大举降息押注
  • 新浪财经.1小时前
  • IMF:全球经济面临中期风险 更宽松并非解决之道
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
+1.19%
制药与医学研究
+0.61%

热门股票

名称
价格
涨跌幅

LCTX 简况

Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).
展开

Webull提供Lineage Cell Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。